Category1 Registration Type Fee
Club Member CSCC Members $150.00 plus applicable taxes
  Non-Members $175.00 plus applicable taxes
Single Roundtable CSCC Members $25.00 plus applicable taxes
  Non-Members $30.00 plus applicable taxes

All CSCC Education Roundtables will be held on Thursdays and will be one (1) hour in length.
Eastern Pacific Mountain Central Atlantic Newfoundland
ON, QC BC AB, SK* MB, ON (West) NB, NS, PE, Lab NL
11:30-12:30 08:30-09:30 09:30-10:30 10:30-11:30 12:30-13:30 13:00-14:00
14:00-15:00 11:00-12:00 12:00-13:00 13:00-1400 15:00-16:00 15:30-16:30
* SK - During daylight savings time; otherwise one hour later

Register HERE Today!

1Save today! Club members are entitled to join any or all of the Roundtables. Register once only and automatically receive an invitation for each Roundtable and access to the slides and recordings of past roundtables for the current year.

  • Registration is by pre-payment only using the online registration form.
  • Each registration is restricted to one (1) phone line; you may have as many participants using that line as you wish.  You are welcome to sign up more than one (1) phone line but each line must be a separate registration and payment. **COVID NOTE** During the pandemic when social distancing rules restrict gatherings, a group registration can apply to multiple lines and all members of the group can log in using their own line. If you are a member of a group please register without making the payment, and indicate your group name in the field provided.
  • Participants will be sent a 1-800 phone number for the audio and an internet url to view the slides.

2021-2022 SCHEDULE

  Date Time (Eastern) Presenter(s) Topic
1.  October 7, 2021 14:00 Laura Smy
Mark A. Cervinski
The journey to incorporating Six Sigma metrics in the clinical laboratory
2.  October 14, 2021 14:00 Frank Courjal Clinical Utility and Technical Advantages of CSF - Free Light Chains in Diagnosis of Multiple Sclerosis
Industry Workshop presented by The Binding Site
3. October 21, 2021 11:30 Yiorgos Alexandros Cavayas Biomarkers of thrombosis, inflammation and organ injury in severe COVID-19
4. October 28, 2021 11:30 Pierre-Olivier Hétu Overview of the installation and evaluation of a fully automated LC-MS/MS clinical analyzer and 25-OH-Vitamin D assay in a clinical laboratory in Canada - potential benefits
Industry Workshop presented by Thermo Fisher Scientific
5. November 4, 2021 11:30 Vincent De Guire
Julie Shaw
Canadian Update on the use of Qls for quality improvement in laboratory medicine
6. November 18, 2021 14:00 Anna Füzéry Point-of-Care Testing in Emergency Medical Services Settings
7. December 2, 2021 11:30 Raymond Lepage Did the clinical chemistry lab really change since 1973?
8. January 13, 2022 11:30 Lisa Johnson Fecal Calprotectin and Pancreatic Elastase Assays
9. January 27, 2022 11:30 Matthew Henderson Newborn Screening for MPS-1 Hurler in Ontario
10. February 10, 2022 14:00 Mari DeMarco Patient and care partner perspectives on Alzheimer’s disease biomarker testing
11. February 24, 2022  11:30 Rahul G. Knishnan  Use of electronic health data in AI predictive models 
12. March 10, 2022  11:30 Todd J. Anderson  Update on the CCS Dyslipidemia Guidelines
13.  March 24, 2022  14:00 CSCC Lectureship   
14. April 7, 2022  11:30 CSCC Lectureship   
15. April 21, 2022  14:00 Andre Mattman  Recognition of adult presentations of inborn errors of hepatic metabolism
16. May 5, 2022  11:30    
17. May 19, 2022 tba    


#15. April 21, 2022 Recognition of adult presentations of inborn errors of hepatic metabolism
Speaker:  Andre M. Mattman, MD, FRCPC, Division Head for Chemistry and Consultant with Adult Metabolic Diseases Clinic, St. Paul's Hospital & Vancouver General Hospital 
Overview:  Adult onset presentations of hepatic inborn errors of metabolism include hyperammonemia, hypoketotic hypoglycemia, intrahepatic cholestasis, epatosplenomegaly, steatohepatitis, cirrhosis and multisystem disease. The clinical and laboratory approach to the recognition of these disorders will be presented. 
Objectives:  At the conclusion of this session, participants will be able to:
1)  Recognize the clinical features which increase the likelihood that an adult presenting with a given hepatic disorder, has an inborn error of metabolism.
2)  When considering a hepatic inborn error of metabolism, identify the appropriate laboratory test for further investigation.
#12. March 10, 2022 Update on the CCS Dyslipidemia Guidelines
Speaker: Todd J. Anderson, Vice Dean, Cumming School of Medicine, University of Calgary
Overview: Abnormalities of lipoproteins are a major cause of ASCVD risk in Canada with at least 1/3 of Canadians having sub-optimal treatment of this risk factor. Even in subjects with previous ASCVD less than 50% of patients are at target levels of atherogenic lipoproteins. The updated CCS dyslipidemia guidelines has addressed a number of PICO questions that will aid clinicians in decreasing atherogenic risk. Laboratory medicine plays an important role with lipid reporting in helping clinicians understand when treatment might be required for a particular lipid value. We will review the current guidelines and discuss new approaches to the role of laboratory medicine in improving the current treatment gap that exists in Canada.
Objectives: At the conclusion of this session, participants will be able to:
1)  understand the current CCS dyslipidemia guidelines for lipoprotein testing and treatment to reduce atherosclerotic CV risk
2)  explore the role of laboratory medicine to aid primary care providers in ASCVD risk determination and optimal treatment of individuals at risk.
#10. February 10, 2022 Patient and Care Partner Perspectives on Alzheimer’s Disease Biomarker Testing
Speaker: Mari DeMarco, PhD, DABCC, FCACB, Clinical Chemist & Clinical Associate Professor, Providence Health Care & University of British Columbia
Overview:  The IMPACT-AD study is an observational, longitudinal cohort study designed to understand the impact of cerebrospinal fluid (CSF) testing for core Alzheimer's disease biomarkers on clinical decision making, diagnosis, health system utilization, and patients and their care partners ( As part of the study, patient participants and their study partners (e.g., a family member) provide feedback on their experience will the entire testing process, from discussing the possibility of testing with their physician, to receiving the test result, to longer-term follow-up on actions taken post-result disclosure. The goal of IMPACT-AD is to collect the first data of its kind on the utility of CSF biomarkers in routine care in Canada, with the overall goal of improving care and support systems for individuals living with neurodegenerative disorders. This presentation will focus on the (i) opportunities for, and steps involved in, patient-oriented research in the context of laboratory medicine, and, (ii) via the IMPACT-AD study, what knowledge we gained from the lived experience of people with neurodegenerative disorders. 
Objectives: At the conclusion of this session, participants will be able to:
1)  Communicate appropriate uses of Alzheimer’s disease cerebrospinal fluid testing to various audiences.
2)  Give examples of how Alzheimer’s disease testing impacts patients and care partners.
3)  Discuss approaches to, and opportunities for, patient-oriented research in laboratory medicine.
#9. January 27, 2022 Newborn Screening for MPS-1 Hurler in Ontario
Speaker: Matthew P.A. Henderson, PhD, FCACB, FCCMG, Biochemist, Newborn Screening Ontario, The Children's Hospital of Eastern Ontario
Overview: Mucopolysaccharidoses type 1 (MPS-1) is a lysosomal storage disorder caused by iduronidase deficiency. MPS-1 Hurler, the severe form of MPS-1, is a lethal progressive multi-system disease with rapid cognitive impairment. Treatment with enzyme replacement therapy and stem cell transplantation is most beneficial if initiated in the first year of life. Newborn Screening Ontario added MPS-1 Hurler to the Ontario newborn screening panel in 2020. This presentation will discuss development of the high-throughput fluormetric iduronidase activity assay used for first tier screening, the combined biochemical and molecular screening process and our experience to date.
Objectives: At the conclusion of this session, participants will be able to:
1)  Provide a brief review of glycosaminoglycan degradation.
2)  Discuss the benefits of newborn screening for MPS-1 Hurler.
3)  Understand the fluormetric iduronidase assay used for first tier MPS-1 Hurler screening.
4)  Discuss the combined biochemical and molecular screening process for MPS-1 Hurler
#8. January 13, 2022 Fecal Calprotectin and Pancreatic Elastase Assays 
Speaker: Lisa Johnson, PhD, DABCC, Assistant Professor, ARUP/University of Utah
Overview: Fecal calprotectin is an inflammatory marker measured in stool that aids in both screening and following patients with inflammatory bowel disease (IBD). Pancreatic elastase is an enzyme measured in stool to screen for exocrine pancreatic insufficiency. Both tests are increasingly ordered by gastroenterologists for patients with abdominal pain and diarrhea. This presentation will discuss both the clinical and analytical benefits and limitations of these two quantitative stool-based assays. 
Objectives: At the conclusion of this session, participants will be able to:
1.  Describe the clinical utility of fecal calprotectin and pancreatic elastase results.
2.  Identify some of the analytical challenges for quantitative measurements in stool.
3.  Discuss considerations for fecal calprotectin and pancreatic elastase assays. 
#7 December 2, 2021 Did the clinical chemistry lab really change since 1973?
Speaker:  Raymond Lepage, Ph.D., Scientific Writer, Biron Groupe Santé 
Overview:  Clinical chemistry laboratories are in apparent constant evolution. This presentation will start with a description of a typical routine lab in a general hospital in the 1970’s as seen from an untrained clinical chemist. This will be followed by the description of some technical, ethical and organisational problems in biochemistry profiles, immunoassays, particularly of early parathyroid hormone measurements. A description of a homebrew assay for glucose measurement on filter paper and the development of quality control of POCT glucose measurements will complete the presentation. At the end of the presentation, the author will comment on the evolution of clinical chemistry over a period of nearly fifty years. 
Objectives:  At the end of this session, participants will be able to:
1)  Evaluate some progress of clinical laboratory medicine over a period of fifty years
2)  Develop a reflecton of their role in a continuously changing environment. 
#6 November 18, 2021 Point-of-Care Testing in Emergency Medical Services Settings
Speaker: Anna Füzéry, North Sector POCT Medical Lead, Alberta Precision Laboratories
Overview: Point-of-care testing (POCT) is used Emergency Medical Services (EMS) settings to assist health care providers in making decisions on patient care while on scene and during transport. The accuracy and reliability of POCT is strongly dependent on the presence of robust quality assurance (QA) practices. National and international guidelines on POCT QA are becoming increasingly available, but their adoption in EMS settings is neither trivial nor straightforward. This presentation will provide attendees with an overview of current barriers to adoption of these guidelines and will describe a recently proposed standard for POCT in EMS settings. The standard incorporates features that are already considered best practice for all POCT, as well as features that aim to mitigate the special challenges encountered in EMS settings. The presentation will also highlight the roles and responsibilities of various groups in the adoption of the proposed standard.
Objectives: At the conclusion of this session, participants will be able to:
1)  Provide a brief overview of the different programs and services provided by EMS in Canada and elsewhere
2)  Provide examples of the clinical utility of POCT in EMS settings
3)  Discuss the challenges and failure modes associated with POCT in EMS settings
4)  Describe a recently proposed standard for POCT in EMS settings
5)  Discuss the roles and responsibilities of laboratories, EMS organizations, POCT device manufacturers, accreditation bodies, regulatory agencies and professional organizations in the adoption of the recently proposed standard
#5 November 4, 2021 Canadian update on the use of Qls for quality improvement in laboratory medicine
Speakers: Dr. Vincent De Guire, Clinical Biochemist, Maisonneuve-hospital, Optilab Montréal-Chum Network
Julie Shaw, Head, Division of Biochemistry and Director of POCT, The Ottawa Hospital, EORLA and The University of Ottawa
Overview: Quality improvement of processes through Quality Indicators (QI) monitoring is essential for patient safety and required for ISO15189 accreditation. As laboratory medicine professionals, assessment of the robustness of our processes through benchmarking and laboratory comparison must be a priority. To achieve this, standardization of QI monitoring between sites as well as a program for comparison are essentials. In this presentation, guidelines and tools available at the national and international level for QI monitoring will be reviewed. Strategies for benchmarking as well as methodology for QIs selection will be discussed. The work of the joint CSCC SIGs (QI and POCT) for selection of QIs in POCT will be presented.
Objectives: At the conclusion of this session, participants will be able to:
1)  Improve their knowledge on initiatives available in Canada for processes improvement and on international guidelines in the QIs field.
2)  Be able to describe strategies for benchmarking and QIs selection based on risk assessment.
3)  Be aware of the Canadian initiative on QIs standardization and comparison in POCT.
#3 October 21, 2021 Biomarkers of thrombosis, inflammation and organ injury in severe COVID-19
 Speaker: Yiorgos Alexandros Cavayas, Intensivist and Assistant Professor of Medicine, Université de Montréal 
 Overview: Through the presentation of clinical cases, we will discuss the use of biomarkers for prognostication, treatment selection and detection of complications in critically ill patients with COVID-19.
 Objectives: At the conclusion of this session, participants will be able to:
1)  Discuss the use of biomarkers to prognosticate patients with COVID-19.
2)  Describe how biomarkers can be used to detect complications of COVID-19.
3)  Discuss how biomarkers may help tailor therapy and monitor patient response.
#1. October 7, 2021 The journey to incorporating Six Sigma metrics in the clinical laboratory
Speaker: Laura Smy, Assistant Professor / Director, Clinical Chemistry and Toxicology, Medical College of Wisonsin / Wisconsin Diagnostic Laboratories
Overview: Six Sigma concepts can be a valuable tool for the clinical lab by aiding with assessing assay quality, devising a quality contol plan, selecting a new analyzer, and improving laboratory processes. The journey to utilizing Six Sigma requires learning the concepts and how they apply to the clinical lab, which is not without some challenges. This presentation will provide an overview of the value of Six Sigma in the clinial lab, examples of the Six Sigma calculation, and outline the factors to consider with the goal of demonstrating that the Six Sigma journey is a trip worth taking for every clinical lab.
Objectives: At the conclusion of this session, participants will be able to:
1. Calculate the Six Sigma metric for an assay
2. Describe how applying Six Sigma in a clinical lab can be valuable
3. List factors to consider when incorporating Six Sigma in the clinical lab
Speaker: Mark A. Cervinski, Director of Clinical Chemistry, Associate Professor of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, and The Geisel School of Medicine at Dartmouth
Overview: Patient based quality control techniques have the potential to provide near real-time information on assay performance, allowing for detection of analytic error far in advance of traditional QC techniques. The concept of patient-based QC for laboratory testing was first proposed nearly 60 years ago, however the field is still in lag-phase growth but may be on the cusp of an exponential increase in use and functionality. Some laboratories are already using patient-based QC techniques to catch analytical error, however patient-based QC is not a panacea and comes with important limitations. In this session I will discuss some of the various techniques currently in practice, as well as the steps taken in my own laboratory to develop and deploy patient-based QC.
Objectives: At the conclusion of this session, participants will be able to;
1)  Determine the assay and population characteristics of an analyte that indicate where patient-based QC can be deployed for the effective detection of systematic error.
2)  Discuss the types of errors that are likely to be detected with patient-based QC